All IndicationsApprovedApprovedPhase 3Phase 2Phase 1
IgA nephropathy
6
Companies
7
Drug Programs
1
Phase 3
0
Upcoming PDUFAs
Competitors
NVS
Novartis
Fabhalta
AZN
AstraZeneca
ravulizumab
KDNY
Chinook Therapeutics, Inc.
Atrasentan
NVS
Novartis AG
BION-1301 Single Dose
CLYM
Climb Bio
CLYM116
OTSKF
Otsuka Pharmaceutical
sibeprenlimab
VERA
Vera Therapeutics
atacicept-vymj
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| NVS Novartis | Fabhalta | Approved | — | — | — |
| AZN AstraZeneca | ravulizumab | Approved | — | — | — |
| KDNY Chinook Therapeutics, Inc. | Atrasentan | Phase 3 | — | — | — |
| NVS Novartis AG | BION-1301 Single Dose | Phase 2 | — | — | — |
| CLYM Climb Bio | CLYM116 | Phase 1 | — | — | — |
| OTSKF Otsuka Pharmaceutical | sibeprenlimab | — | — | — | — |
| VERA Vera Therapeutics | atacicept-vymj | — | — | — | — |
Development Stage Distribution
Unknown
2
Approved
2
Phase 3
1
Phase 2
1
Phase 1
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.